


**VS\_IL3\_AND\_HIVP17\_STIM\_PDC\_DN, GSE10147\_IL3\_VS\_IL3\_AND\_HIVP17\_STIM\_PDC\_DN**  GSE40274\_FOXP3\_VS\_FOXP3\_AND\_SATB1\_TRANSDUCED\_ACTIVATED\_CD4\_TCELL\_UP, GSE40274\_FOXP3\_VS\_FOXP3\_AND\_SATB1\_TRANSDUCED\_ACTIVATED\_CD4\_TCELL\_UP  
HARALAMBIEVA\_PBMCM\_M\_R\_II\_AGE\_11\_22YO\_VACCINATED\_VS\_UNVACCINATED\_LOW\_ANTIBODY\_RESPONDERS\_TO\_TREATMENT\_7YR\_DN, HARALAMBIEVA\_PBMCM\_M\_R\_II\_AGE\_11\_22YO\_VACCINATED\_VS\_UNVACCINATED\_LOW\_ANTIBODY\_RESPONDERS\_TO\_TREATMENT\_7YR\_DN